Custom HuCAL® Monoclonal Antibody Generation Service

Find out how a new service to provide custom recombinant antibodies with a SpyTag can advance your research, and also contributes towards reducing the use of animals in science.

Monitoring of immune responses caused by biotherapeutic drug treatment is a regulatory requirement during preclinical development through to clinical trials. Optimization and validation of assays for anti-drug antibodies (ADA) is challenging, particularly when the drug itself is a human monoclonal antibody, due to the excess of human antibodies in serum and the relatively low immune response. Highly specific and sensitive detection antibodies are needed for robust pharmacokinetic (PK) and anti-drug antibody (ADA) assays. In this application note, Bio-Rad highlights a faster route to more sensitive assays for the monitoring of drug antibodies.

Sensitive and reproducible pharmacokinetic (PK) and immunogenicity assays are required as part of the complex and lengthy development process for biotherapeutic proteins. These assays are included in a range of approaches applied to understand the nature and properties of the drug as well as the induction of anti-drug antibodies (ADA) against the target, which can cause adverse events and loss of efficacy. In this application note, Bio-Rad explores the use of fully human, anti-idiotypic antibodies for PK and immunogenicity assays.

Advances in the development of biotherapeutic proteins, such as monoclonal antibodies, enzymes and toxins, bode well for future improvement of human health. Drug safety and efficacy are key concerns for the manufacturer during the long, complex and costly development process. In addition regulatory agencies now expect that immune responses caused by drug treatment are monitored during preclinical development and clinical trials. Immune responses leading to the generation of anti-drug antibodies (ADA) can cause adverse events, but the most common problem is loss of efficacy, when ADAs bind the drug and neutralize its activity or speed up its biological elimination.

In this brochure, find out what is offered in Bio-Rad's monoclonal antibody service designed to generate antibodies to meet your precise requirements.

In this application note, Bio-Rad outlines how HuCAL PLATINUM technology can generate antibody reagents that offer highly specific recognition of the drug-target complex for several approved therapeutic antibodies. Alongside type 1 and type 2 antibody reagents, these type 3 and type 4 antibodies are extremely valuable additions to the LBA toolbox and may enable the development of more sophisticated analysis tools for biotherapeutics.

This application demonstrates how Human Combinatorial Antibody Library (HuCAL® ) technology can be used to isolate chimeric antibodies for in vivo target validation studies in a multitude of disease models. In this example, Bio-Rad focuses on a mouse model of myocardial infarction, demonstrating the therapeutic potential of inhibiting MASP-2. 

This application note demonstrates that high-quality antibodies isolated from the HuCAL PLATINUM® library can discriminate between agonist and antagonist forms of CXCL10 differing by only two amino acids. Here, Bio-Rad explores how its technology could be used to improve clinical outcomes from hepatitis C virus (HCV) treatment and point to novel targets for therapeutics.

In this application note, Bio-Rad demonstrates how the Human Combinatorial Antibody Library (HuCAL®) technology was used to isolate antibodies specific to the active site of the West Nile Virus NS2B-NS3 proteinase complex, providing antibody research tools that enabled scientists to carry out inhibition experiments and structural studies.

This application note highlghts how Bio-Rad's custom antibody team generated fully human IgA antibodies and used their expertise in recombinant antibody generation, in collaboration with immunodiagnostic assay experts, to develop a solution to the challenge of standardization for anti-cardiolipin antibody (ACA) assays.

In this video, see inside Bio-Rad's custom antibody facility and learn from antibody experts on how your requirements for specialized custom antibodies can become a reality through the use of HuCAL® technology.

Dr. Christian Frisch explains how to design a reliable assay and reveals how Bio-Rad and Sartorius teamed up to help scientists achieve peak immunoassay performance

Watch this on demand webinar to learn about SpyTag-SpyCatcher technology and how TrailBlazer Antibodies can transform your assay development

Dr. Jacqueline Barnett and Dr. Joel Allainguillaume discuss their work to develop handheld detectors to combat the spread of cacao swollen shoot virus and arrest the decline in the cocoa industry

Discover how AFABILITY founder Dr. Alison Gray is enabling the transition from animal-derived to non-animal-derived antibodies

Join us on Wednesday, October 28, to learn how SpyTag-SpyCatcher technology enables site-directed conjugation and rapid assembly of different antibody format

Dr. Carol Treasure discusses her hopes to accelerate the world’s transition to completely animal-free testing, to produce safe cosmetics and improve skin sensitization testing

R&D expert Dr. Francisco Ylera shares the secret to fast and flexible formatting of antibodies to accelerate your research